1-3 of 3
Michelle Dolan, MD
Close
Sort by
Journal Articles

Prognostic Significance of Cytogenetic Abnormalities in Patients with Philadelphia-Negative ALL Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in Complete Remission: A CIBMTR Analysis

Aleksandr Lazaryan, MD PhD MPH, Michelle Dolan, MD, Mei-Jie Zhang, PhD, Hai-Lin Wang, MPH, Veronika Bachanova, MD PhD, Marcos De Lima, MD, Brenda M. Sandmaier, MD, Daniel J. Weisdorf, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1439.
https://doi.org/10.1182/blood.V130.Suppl_1.1439.1439
Published: 2017
Journal Articles

Relapse Prediction Post Allogeneic Hematopoietic Cell Transplant for Myelodysplastic Syndromes Is Not Improved with Use of the More Stringent Blast Percentage Categories in the Revised International Prognostic Scoring System

Leyla Shune, MD, Zohar Sachs, MD, PhD, Todd E. Defor, MS, Michelle Dolan, MD, Daniel J. Weisdorf, MD, Celalettin Ustun, MD, Erica D. Warlick, MD
Journal: Blood
Blood (2012) 120 (21): 2011.
https://doi.org/10.1182/blood.V120.21.2011.2011
Published: 2012
Journal Articles

Monosomal Karyotype Provides Better Prognostic Prediction After Allogeneic Stem Cell Transplantation in AML Patients.

Betul Oran, MD, MS, Michelle Dolan, MD, Linan Ma, M.S.P.H., Claudio Brunstein, MD, PhD, Erica Warlick, MD, Daniel J. Weisdorf, MD
Journal: Blood
Blood (2009) 114 (22): 525.
https://doi.org/10.1182/blood.V114.22.525.525
Published: 2009